Zai Lab Shares Outstanding 2016-2021 | ZLAB

Zai Lab shares outstanding history from 2016 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Zai Lab shares outstanding for the quarter ending June 30, 2021 were 0.093B, a 27.54% increase year-over-year.
  • Zai Lab 2020 shares outstanding were 0.078B, a 20.66% increase from 2019.
  • Zai Lab 2019 shares outstanding were 0.064B, a 22.35% increase from 2018.
  • Zai Lab 2018 shares outstanding were 0.053B, a 141.85% increase from 2017.
Zai Lab Annual Shares Outstanding
(Millions of Shares)
2020 78
2019 64
2018 53
2017 22
2016 9
2015 9
Zai Lab Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 93
2021-03-31 88
2020-12-31
2020-06-30
2020-03-31 73
2019-12-31
2019-09-30
2019-06-30
2018-12-31
2017-12-31
2017-06-30
2016-12-31
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $9.514B $0.049B
Zai Lab Ltd is a biopharmaceutical company. It focused on medicines for cancer, autoimmune and infectious diseases primarily in China. The company's product pipeline consists of ZL-2306, ZL-2401, ZL-2301, ZL-3101, ZL-2302 and ZL-1101 which are in clinical stage. Zai Lab Ltd is based in Pudong, China.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $128.460B 8.55
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.211B 20.68
Biohaven Pharmaceutical Holding (BHVN) United States $8.952B 0.00
Emergent Biosolutions (EBS) United States $2.717B 6.55
Arcus Biosciences (RCUS) United States $2.502B 0.00
Myovant Sciences (MYOV) United Kingdom $1.906B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.820B 0.00
Zymeworks (ZYME) Canada $1.088B 0.00
Ambrx Biopharma (AMAM) United States $0.513B 0.00
SQZ Biotechnologies (SQZ) United States $0.343B 0.00
Enzo Biochem (ENZ) United States $0.159B 15.57